Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | PYGL | P06737 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31036179 | 0.89 | HSD17B10 (0.60) | HDAC1HDAC8LMNA | |
| SCHEMBL16728220 | 0.86 | L3MBTL1 (0.68) | HPGDHDAC1HDAC8CYP1A2GAA | |
| SCHEMBL6502555 | 0.86 | HPGD (0.60) | HPGDHDAC1HDAC8POLBGAA | |
| SCHEMBL1093862 | 0.82 | HPGD (0.91) | HPGDHDAC1HDAC8HDAC3GAA | |
| SCHEMBL31036028 | 0.81 | HDAC1 (0.60) | HDAC1HDAC8CYP1A2 | |
| SCHEMBL31036034 | 0.81 | HDAC1 (0.60) | HDAC1HDAC8CYP1A2 | |
| SCHEMBL9425343 | 0.80 | TRPV1 (0.75) | HPGDCYP1A2POLBKDM4ELMNA | |
| SCHEMBL934187 | 0.80 | HPGD (0.61) | HPGDHDAC1HDAC8HDAC3GAA | |
| SCHEMBL13652571 | 0.80 | MTNR1A (0.62) | HDAC1HDAC8POLBGAAKDM4E | |
| SCHEMBL9679759 | 0.80 | CYP1A2 (0.71) | HDAC1HDAC8CYP1A2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556361-A2 | 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004037797-A2 | 2 - ALKYL - (2 - AMINO - 3 - ARYL - PROPIONYL) - PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2004-05-06 | — | — | WO | claimed |
| WO-2022178592-A1 | SOLID PHASE SYNTHESIS OF GLUTAMATE-UREA-LYSINE DERIVED (GUL DERIVED) PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETING CONJUGATES AND THEIR USE AS PRECURSORS FOR THERAPEUTIC AND / OR DIAGNOSTIC AGENTS | Telix International Pty Ltd (AU) | 2022-09-01 | — | — | WO | disclosed |
| US-20200353109-A1 | A DOUBLE-LABELED PROBE FOR MOLECULAR IMAGING AND USE THEREOF | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353109-A1 | A DOUBLE-LABELED PROBE FOR MOLECULAR IMAGING AND USE THEREOF | CD47, ANXA5, ANXA1 | HPGD 1906/4885HDAC1 1549/4885HDAC8 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.